Get the Stockscreener App
6.81
0.59%
0.04
Nuvation Bio Inc stock is traded at $6.81, with a volume of 3.76M.
It is up +0.59% in the last 24 hours and up +5.75% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
See More
Previous Close:
$6.77
Open:
$6.78
24h Volume:
3.76M
Relative Volume:
0.57
Market Cap:
$2.39B
Revenue:
$143.05M
Net Income/Loss:
$-145.99M
P/E Ratio:
-15.90
EPS:
-0.4282
Net Cash Flow:
$-134.06M
1W Performance:
+2.25%
1M Performance:
+5.75%
6M Performance:
+43.67%
1Y Performance:
+99.12%
1-Day Range:
$6.72
$6.87
1-Week Range:
$6.485
$7.1301
52-Week Range:
$2.99
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
332-208-6102
Address
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
6.81 | 2.40B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Nuvation Bio | 4: Statement of changes in beneficial ownership of securities-Officer Hattersley Gary - Moomoo
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com Canada
Nuvation Bio stock rises after Cantor starts at Overweight - Investing.com
Nuvation Bio rises as Cantor initiates at overweight - Seeking Alpha
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com India
JPMorgan sees 100% upside in overlooked cancer drug stock - thestreet.com
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma - AllSci
Nuvation Bio receives FDA fast track status for brain cancer drug - Investing.com South Africa
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma - PR Newswire
Market Sentiment Around Loss-Making Nuvation Bio Inc. (NYSE:NUVB) - Moomoo
One NYSEListed Biotechnology Stock at Resistance Level – NUVB - kalkine.ca
Nuvation (NUVB) Results Breakdown: EPS Comes in Above Forecast for the Current Session; Share Response - Vinanet
Nuvation Bio (NUVB) Institutional Ownership 2026 - MarketBeat
This cancer drug stock could double as its treatment hits the market, JPMorgan says - CNBC
Nuvation wins new Overweight at J.P. Morgan (NUVB:NYSE) - Seeking Alpha
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know - Yahoo Finance
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
JPMorgan Initiates Nuvation Bio at Overweight With $13 Price Target - marketscreener.com
JPMorgan initiates Nuvation Bio stock coverage with overweight rating By Investing.com - Investing.com South Africa
JPMorgan initiates Nuvation Bio stock coverage with overweight rating - Investing.com
The Manufacturers Life Insurance Company Reduces Stake in Nuvation Bio Inc. $NUVB - marketbeat.com
Nuvation Bio (NUVB) Is Down 5.8% After Wider Q2 Loss Despite Surging Revenue And IBTROZI Focus - simplywall.st
Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Nuvation Bio (NUVB) Could Be 69% Undervalued On Earnings And IBTROZI Data Focus - Sahm
Brokers Set Expectations for Nuvation Bio FY2026 Earnings - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
559,180 Shares in Nuvation Bio Inc. $NUVB Bought by Renaissance Technologies LLC - marketbeat.com
Power Solutions International And 2 More Growth Stocks With Strong Insider Ownership - simplywall.st
HC Wainwright Predicts Nuvation Bio Q1 Earnings - MarketBeat
Nuvation Bio Q2 Earnings Call Highlights - marketbeat.com
Nuvation Bio Inc (NUVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Nuvation Bio(NUVB.US), With a Forecast Between $12 to $21 - moomoo.com
Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $13 - Moomoo
RBC Adjusts PT on Nuvation Bio to $20 From $19, Maintains Outperform Speculative Risk Rating - marketscreener.com
Why Nuvation Bio (NUVB) Is Down 8.8% After Surging Q2 2026 Revenue and IBTROZI Data Tease - simplywall.st
NUVB SWOT Analysis: Revenue Surge Amidst Ongoing Losses Revealed in 10-Q Filing - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc - The National Law Review
Earnings call transcript: Nuvation Bio tops revenue forecasts in Q2 2026 - Investing.com Nigeria
Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results - MarketBeat
Nuvation Bio Inc. Stock 12‑Month Price Target Raised to $12.89, Implies 102% Upside - TradingView
Nuvation Bio earnings missed by $0.03, revenue topped estimates - Investing.com
Nuvation Bio Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Nuvation Bio reports Q2 revenue of $31.7 million - Investing.com
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Nuvation Bio Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (NUVB) Nuvation Bio Posts Q2 Net Loss of $0.18 per Share, vs. FactSet Est of $0.15 Loss - marketscreener.com
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q2 Revenue $31.7M, vs. FactSet Est of $27.0M - marketscreener.com
Nuvation Bio posts $31.7M Q2 revenue, $23.2M IBTROZI product sales and $62.8M net loss - TradingView
BRIEF-Nuvation Bio Q2 EPS USD -0.18 - TradingView
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvation Bio Inc Stock (NUVB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER |
Aug 19 '26 |
Sale |
7.09 |
100,000 |
709,240 |
0 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):